A woman kneels to help a young girl with her coat in a softly lit, emergent entryway, where shoes and bags are scattered nearby and sunlight streams through the window and door in the background.

PREPAREDNESS TODAY, SAFER TOMORROW.

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada

Emergent has announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to support Canada’s biological threat preparedness and response infrastructure.

LEARN MORE

The New Way Forward

Who we protect will not change, but how we protect them will. Emergent is leading the new way forward for public health.

Learn more

Capabilities

We are a leading public health company that delivers protective and life-saving solutions to communities around the world.

  • We offer commercialized products that address endemic public health threats such as the opioid epidemic.

  • We specialize in developing, manufacturing, and supplying medical countermeasures for national security and public health preparedness.

  • We leverage our specialized in-house capabilities to support biopharma innovators, governments and non-government organizations with their development and manufacturing needs. ​

A man in a pink shirt looks up while standing next to a whiteboard covered in emergent blue and orange writing in a dimly-lit room.

At Emergent, our mission is to protect and save lives.

View our 2024 Annual Report

Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility

GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company has closed on a new credit facility agreement with OrbiMed for a new $150 million term loan.
Read More

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m. eastern time to discuss the financial results for the first quarter of 2026.
Read More

Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program

WINNIPEG, Manitoba, April 09, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced that it has partnered with the B.C. Provincial Health Services Authority (PHSA) to supply NARCAN® Nasal Spray for the province’s Take-Home Naloxone Program (BC THN Program).
Read More
READ ALL NEWS